iwCLL 2023 | Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
John Allan, MD, Weill Cornell Medicine, New York, NY, discusses an update of the Phase II CAPTIVATE trial (NCT02910583) of ibrutinib plus venetoclax in front-line treated young patients with chronic lymphocytic leukemia (CLL). Dr Allan and his co-authors analyzed trial data of patients with high-risk features and found high rates of MRD-negativity following treatment, likely due to the disease being highly sensitive to this combination of agents in these individuals. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
